Table 1.
Demographic and clinical characteristics of study cohorts.
| Blood | Decidua | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| G0 | I trimester | II trimester | III trimester | Post | ||||||||
| HC (n = 17) | MS (n = 10) | HC (n = 8) | MS (n = 11) | HC (n = 13) | MS (n = 11) | HC (n = 11) | MS (n = 11) | HC (n = 9) | MS (n = 6) | HC (n = 19) | MS (n = 8) | |
| Age, years, median (interquartile range)† | 28.53 (24–28.53) |
28.5 (22.5–35.5) |
34.5 (31.5–38.5) |
34 (31–36) |
34 (31–35) |
33 (30–35.5) |
33 (31–36.5) |
33 (30.5–35.5) |
35.33 (32–37) |
33.5 (30.25–36.75) |
34.5 (30.25–39.25) |
33.5 (32.25–36.5) |
| Previous miscarriages, n (%)* | 1 (20.0) |
4 (44.4) |
2 (22.2) |
3 (30.0) |
1 (12.5) |
3 (30.0) |
1 (11.1) |
2 (33.3) |
4 (22.2) |
2 (25.0) |
||
| Caesarean section, n (%) | 19 (100) |
5 (62.5) |
||||||||||
| Disease duration, months, median (interquartile range)§ | 22.5 (11–46.75) |
59 (46.75–73.50) |
72 (53–90) |
75 (56.5–90.5) |
74 (63.25–88.50) |
139.5 (107.5–169.8) |
||||||
| EDSS, median (interquartile range)† | 0.5 (0–1.75) |
1 (0.25–1.37) |
1 (0–1.75) |
1 (0–1.25) |
1 (0.25–3.62) |
1 (1–1.25) |
||||||
| Previous therapy, n (%) | ||||||||||||
| IFNβGlatiramer acetateNatalizumabNone | 4 (36.4) 3 (27.3) 1 (9.1) 3 (27.3) |
5 (45.4) 4 (36.4) 1 (9.1) |
6 (54.5) 3 (27.3) 1 (9.1) |
3 (50.0) 2 (33.3) 1 (16.6) |
4 (50.0) 3 (37.5) 1 (12.5) |
|||||||
| Months of wash out from therapy, median (interquartile range)† | 1 (1–4.25) |
4 (3–5) |
7 (6–7) |
7 (7–7.75) |
8 (7.5–13.5) |
|||||||
†
Kruskal–Wallis test, p > 0.05.
*
Total observations may change due to missing data.
§
Kruskal–Wallis test, p = 0.02 (Dunn's post-hoc test: G0 vs. post, p = 0.04; G0 vs. decidua, p = 0.02); MS, multiple sclerosis; HC, healthy controls; IFNβ, interferon beta.